Truscreen Group Ltd. · NZX:TRU
Truscreen — Shareholder Meeting (September 2018)
12 slides from Truscreen's shareholder meeting presentation, September 2018
Slide 1: Shareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018
Slide 2: FY18 Highlights
FY 18 HIGHLIGHTS • Strong sales growth of 2nd Gen TruScreen to China commenced during 4th quarter. (50% of the year’s sales were generated in the fourth quarter) • Completed the testing and validation in February 2018 of its second-generation device including in market clinical trials where impressi
Slide 3: FY18 Highlights: Key Financials
FY 18 HIGHLIGHTS KEY FINANCIALS FY18 As at 31 March 2018 Sales $804,062 (up 37% on FY17) Other income $1,374,581 Revenue from Ordinary Activities $2,178,643 (up 56% on 2017) Net Loss $(4,168,792) Net Assets $11,615,882 Cash and Cash Equivalents $1,212,454 TruScreen 2018 Annual Meeting Presentation 3
Slide 4: Sales Growth
SALES GROWTH Sales Q1 FY19 > Total Sales FY18 QUARTERLY SALES CFDA Approves TruScreen2: 4 December 2017 First Post CFDA Sales orders from China: 20 Dec 2017 TS2 under evaluation by CFDA: Q2 FY17 though to end Q3 FY 18 CE Mark TS1 Stocks sold received for out Q4 FY17 TruScreen2 April 2016 Q1 Q2 Q3 Q4
Slide 5: Regulatory and Clinical
REGULATORY AND CLINICAL CLNICAL EVALUATION OF TRUSCREEEN: Ongoing clinical performance evaluation at the Royal Hospital for Women in Sydney and at two regional clinics in Australia. Ongoing results indicate that TruScreen will substantially boost screening capabilities in developing countries. CORE
Slide 6: China
CHINA ▪ Major new sub distributor (Bio-Chem) appointed to manage government sales CHINA: THE FACTS channels ▪ 400 million women of screening age ▪ 16 County hospitals conducting Centre for Disease Control evaluation & 3,000 community healthcare centres throughout rural China ▪ Initial distribution a
Slide 7: India and Mexico
INDIA AND MEXICO ▪ Engaged major distributor in Mar 2017 – KLAB, with • Clinical Trial showed TruScreen more than twice as sensitive as pap in 700 employees identifying high grade cervical changes (CIN2+) ▪ In Dec 2017 commenced Stage 1 (due to conclude • Endorsement by National Cancer Institute – S
Slide 8: Africa & Zimbabwe - Potentially a Significant Market
AFRICA & ZIMBABWE - Potentially a Significant Market ▪ Zimbabwe Ministry of Health support for major funding application (up to AFRICA: THE FACTS $30m over 4 years) to use TruScreen for a national screening program ▪ 227 million women of screening age ▪ First order received for approx. $450k by Nati
Slide 9: Subsequent Activities
SUBSEQUENT ACTIVITIES The company has made significant progress since the end of the 2018 financial year. The key matters include the following: • Sales to 30 September 2018 expected to be $1.578m (previous year $NZD 226K) and for the 12 months to 31 March 2019 budget $5.53m (previous year $0.804m).
Slide 10: FY19 Goals and Objectives
FY19 GOALS AND OBJECTIVES • Expand sales by + 500% • Achieve monthly profitability by year’s end • Consider dual listing and / or migration to a larger exchange • Consumate and expand government screening opportunities • Achieve inclusion in Chinese, Indian and Mexican government programs • Initiate
Slide 11: Contact us for more information
Contact us for more information www.TruScreen.com Martin Dillon Chief Executive Officer TruScreen Ltd T: +61 2 9091 7475 E: [email protected] TruScreen 2018 Annual Meeting Presentation 11
Slide 12: Disclaimers
Disclaimers This presentation should be viewed in conjunction with TruScreen’s Financial Statements for the 12 months to 31 March 2018 and the accompanying NZX release. The information presented is a snapshot and does not contain supporting information necessary to make an investment decision. It is
TruScreen Group — Shareholder Meeting (September 2018) on 6ix